Clinical TrialJun 8, 2026, 08:35 AM
AIM ImmunoTech Reports Positive Phase 2 Ampligen Pancreatic Cancer Progress
AI Summary
AIM ImmunoTech Inc. announced positive progress in its ongoing Phase 2 DURIPANC clinical study, evaluating Ampligen in combination with AstraZeneca's Imfinzi for metastatic pancreatic cancer. The company recently enrolled the final patient and expects to evaluate the primary endpoint, Clinical Benefit Rate, by December 2026. This follows promising data from a prior Named Patient Program where Ampligen monotherapy extended median survival and improved quality of life, particularly in a subgroup with favorable immune markers. AIM ImmunoTech is now planning a pivotal Phase 3 clinical trial to further demonstrate Ampligen's potential.
Key Highlights
- AIM ImmunoTech reported positive progress in its Phase 2 DURIPANC clinical study for Ampligen in metastatic pancreatic cancer.
- The study evaluates Ampligen combined with AstraZeneca's Imfinzi in patients with stable disease post-FOLFIRINOX.
- Enrollment of the final patient in the Phase 2 trial was recently announced.
- Evaluation of the primary endpoint, Clinical Benefit Rate (CBR), is planned for December 2026.
- A previous Named Patient Program (NPP) showed Ampligen monotherapy associated with median survival of 19.7 months, an 8.6-month extension over standard of care.
- In NPP subjects with Neutrophil/Lymphocyte ratios less than 4.5, median survival was 34.8 months vs. 12.5 months for historical controls.
- The company is planning a pivotal Phase 3 clinical trial for Ampligen in combination with a PD-1 inhibitor.
Price Impact
More from AIM